Ischemic Cardiomyopathy Clinical Trial
— PERFECTOOfficial title:
Post-stenting Assessment of Reendothelialization With OFDI After CTO Procedure
Verified date | April 2021 |
Source | Poitiers University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of PERFECTO is to assess the reendothelialization at 3 months after successfully CTO percutaneous intervention (PCI) with new generation drug eluting stent (DES) by OFDI analysis. Designed as a multicentric, observational and prospective study which will be conducted at University Hospital of Poitiers (France), a systematic OFDI analysis will be realized immediately after CTO-PCI and at 3 months. Known as major predictive factors of stent thrombosis, percentages of malapposition, uncovered struts and neointimal hyperplasia proliferation will be measured over the entire length of each stent implanted combining in a composite primary endpoint.
Status | Completed |
Enrollment | 122 |
Est. completion date | February 12, 2021 |
Est. primary completion date | February 12, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Successfully CTO revascularization by PCI with immediate post-PCI OFDI analysis - 3 months follow-up with OFDI analysis of the recanalized coronary artery - Aged 18 or over - Written informed consent Exclusion Criteria: - Contraindication or impossibility to realize a safety coronary OFDI (severe tortuosities) - Severe renal insufficiency (creatinine clearance < 30 ml/min) - Pregnancy or women with child-bearing potential - Bacteriemia or septicemia - Severe hemodynamic instability - Severe coagulation disorders |
Country | Name | City | State |
---|---|---|---|
France | CHU de Clermont-Ferrand | Clermont-Ferrand | |
France | GHM de Grenoble | Grenoble | |
France | Bressollette | Nantes | |
France | CHU de Nimes | Nimes | |
France | CHU Poitiers | Poitiers | |
France | Institut A.Tzanck | Saint Laurent Du Var | |
France | CHU de Toulouse | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Poitiers University Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of uncovered stent struts | Measured by OFDI 3 months after CTO recanalization every millimeter over entire length of each stent implanted. (Number uncovered struts x 100)/total number of struts. | 3 months | |
Primary | Percentage of malapposed stent struts | Measured by OFDI 3 months after CTO recanalization every millimeter over entire length of each stent implanted. (Number of malapposed struts x 100)/total number of struts. | 3 months | |
Primary | Percentage of neointimal hyperplasia proliferation | Measured by OFDI 3 months after CTO recanalization every millimeter over entire length of each stent implanted. [(minimal stent area - minimal lumen area)/minimal stent area]x100. | 3 months | |
Primary | Minimal lumen area | Measured by OFDI 3 months after CTO recanalization every millimeter over entire length of each stent implanted. | 3 months | |
Primary | Minimal lumen diameter | Measured by OFDI 3 months after CTO recanalization every millimeter over entire length of each stent implanted | 3 months | |
Primary | Thrombus | Measured by OFDI 3 months after CTO recanalization every millimeter over entire length of each stent implanted. | 3 months | |
Primary | Edge dissection | Measured by OFDI 3 months after CTO recanalization every millimeter over entire length of each stent implanted. | 3 months | |
Secondary | Relevancy of immediate post-PCI OFDI analysis | To estimate the percentage of patients in whom the post-stenting OFDI analysis will reveal a suboptimal result of angioplasty whereas final angiography was considered optimal, as assessed by the presence of one or more of the following criteria:
Dissection or thrombus. Residual stenosis. Stent malapposition defined by at least one malapposed strut. Residual stenosis. |
Day one | |
Secondary | Impact of the technique employed for CTO revascularization on the reendothelialization | Comparison of primary composite endpoint between different way of recanalization:
Anterograde. Retrograde. Dissection/re-entry. |
3 months | |
Secondary | One year clinical follow-up | Each participating center will perform one year after CTO PCI a clinical evaluation of all patients included. This could be established directly with the subject during medical follow-up or indirectly via family doctor. Standardized questionnaire will be provided at the end of the e-case report form (CRF). Occurrence of major adverse cardiac events (myocardial infarction, death, stroke), sudden death, hospitalization for cardiac disease and severe hemorrhage will be recorded. Any new coronary arteriography will be noticed, as well as any PCI or coronary artery bypass graft (CABG) during this one-year follow-up.
Death all-cause Myocardial infarction Stroke Sudden death Hospitalization for cardiac cause Severe hemorrhage |
One year | |
Secondary | Angina | About symptoms, the Canadian Cardiovascular Society (CCS) grading system and New York Heart Association functional classification will be used to assess respectively exertion-induced angina and dyspnea, and compared to symptoms recorded before CTO revascularization. | One year | |
Secondary | Dyspnea | About symptoms, the Canadian Cardiovascular Society (CCS) grading system and New York Heart Association functional classification will be used to assess respectively exertion-induced angina and dyspnea, and compared to symptoms recorded before CTO revascularization. | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04066738 -
Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy
|
N/A | |
Recruiting |
NCT03536052 -
Ablation at Virtual-hEart pRedicted Targets for VT
|
N/A | |
Enrolling by invitation |
NCT02930265 -
Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy
|
N/A | |
Completed |
NCT01215253 -
Ranolazine Implantable Cardioverter-Defibrillator Trial
|
Phase 3 | |
Completed |
NCT04508608 -
Scintigraphic Evaluation of Contractile and Coronary Reserve in Patients With Ischemic Cardiomyopathy
|
||
Recruiting |
NCT05888662 -
Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT)
|
N/A | |
Completed |
NCT03857906 -
Evaluation of Prophylactic Use of a Preoperative IABP in High-Risk Coronary Artery Bypass Graft Surgery
|
||
Completed |
NCT02501811 -
Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
|
Phase 2 | |
Recruiting |
NCT02058771 -
Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
|
||
Not yet recruiting |
NCT01946048 -
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy
|
Phase 1 | |
Terminated |
NCT01759212 -
Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT01447069 -
Use of Beta-agonists in Stable Severe Congestive Heart Failure
|
N/A | |
Recruiting |
NCT00972114 -
CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy
|
Phase 1/Phase 2 | |
Completed |
NCT00896142 -
Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation)
|
N/A | |
Recruiting |
NCT01076660 -
Left Ventricular Structural Predictors of Sudden Cardiac Death
|
||
Completed |
NCT00305240 -
MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
|
N/A | |
Completed |
NCT00305214 -
MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
|
N/A | |
Active, not recruiting |
NCT00962364 -
Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
|
||
Recruiting |
NCT05769036 -
Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients
|
N/A | |
Completed |
NCT03862339 -
The SoundScar Study The SOUNDSCAR Study
|